LDL, MDA treated Antibody (5D8) [Janelia Fluor® 646]

Product Discontinued

LDL, MDA treated Antibody (5D8) [Janelia Fluor® 646] Summary

• Description:
  
  Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
• Immunogen: Low-density lipoprotein purified from human plasma and treated with MDA and adsorbed onto aluminum hydroxide gel
• Specificity: Reacts with MDA-treated LDL but not with native LDL
• Isotype: IgG1 Lambda
• Clonality: Monoclonal
• Host: Mouse
• Purity: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Western Blot
• Application Notes: Optimal dilution of this antibody should be experimentally determined.

Reactivity Notes

Chemical

Packaging, Storage & Formulations

• Storage: Store at 4C in the dark.
• Buffer: 50mM Sodium Borate
• Preservative: 0.05% Sodium Azide
• Purity: Protein A or G purified

Alternate Names for LDL, MDA treated Antibody (5D8) [Janelia Fluor® 646]

• Low density lipoprotein
• MDA oxidized LDL
• MDA oxidized low density lipoprotein

Background

Low-density lipoprotein (LDL) is the carrier protein for cholesterol in the blood. LDL binds to its receptor on the capillary walls and thereby mediates the uptake and clearance of cholesterol from the circulation. In atherosclerotic lesions oxidatively modified LDL is found and oxidized LDL is specifically recognized and ingested by macrophages via scavenger receptor A and CD36. Oxidized LDL may be a marker of atherosclerosis but the precise changes in oxidized LDL are not well described. MDA-treated LDL appear to be different from LDL oxidized by other means.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.